Abatacept (Orban Biotech)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAbatacept (Orban Biotech)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 inhibitorsCytotoxic T-Lymphocyte-Associated Antigen 4 stimulants
TargetsT-cell-specific surface glycoprotein CD28Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrban BiotechThe National Institute Of Diabetes And Digestive And Kidney Diseases
China Registration ClassN/A

Develop Information

Active CompaniesOrban BiotechThe National Institute Of Diabetes And Digestive And Kidney Diseases
Inactive CompaniesNational Institute Of Diabetes And Digestive And Kidney Diseases
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A